

Headache in kidney transplantation

Ferdinando Maggioni · Maria Cristina Mantovan · Paolo Rigotti · Roberto Cadrobbi · Federico Mainardi · Edoardo Mampreso · Mario Ermani · Silvia Cortelazzo · Giorgio Zanchin

Received: 28 May 2009 / Accepted: 30 July 2009 / Published online: 27 August 2009
© Springer-Verlag 2009

Abstract The aim of this retrospective study was to determine the relevance of the symptom “headache” in kidney transplanted patients, since few studies have considered headache as a clinically significant complication in this condition. A total of 83 consecutive kidney transplant patients underwent to neurological examination and a detailed headache history was taken. The headache history considered the period before kidney disease, during renal failure, during dialysis treatment and after transplantation. Diagnosis was made according to International Headache Criteria (ICDH-II) (2004). Our results reveal an occurrence of headache after kidney transplantation in 44.5% of the patients, which is higher than rates reported for the general population and in the only specific comparable study on liver transplant patients. These data suggest the need for prospective studies to explore the causal mechanisms by which headache develops with frequency in kidney transplant patients, and in particular to determine the role of immunosuppressive therapy.

Keywords Headache · Migraine · Kidney transplantation · Cyclosporine

Introduction

One of the most outstanding contributions to modern medicine has been the introduction of therapeutic organ transplantation. Despite their spectacular and resolutive nature, these procedures are not free of complications in transplant recipients. Neurological problems in particular, occur with a frequency of 20–60%, depending on the organ transplanted [1]. The percentage is higher for heart and bone marrow transplants, and lower in kidney recipients [1]. Neurological complications can be subdivided into those common to all transplants and those specific for a given type of transplant. Headache, in particular, is a non-specific complication with a prevalence that varies between 3.2 and 35.2% according to the studies [2, 3]. Whereas major complications occurring after transplantation have been investigated [4–6], headaches are infrequently discussed as a clinically significant problem in the transplant literature, since they are generally considered less important than other complications such as encephalopathy, infectious diseases of the central nervous system, blood hypertension, organ rejection, therapy with cyclosporine or FK 506 [1, 7–10]. However, headaches have an important negative effect on life satisfaction of these patients according to Matas et al. [11]. To the best of our knowledge, only one study specifically dealt with headaches, and in particular migraine [3]. Other publications involve only case reports [12–17]. Table 1 summarises data published on the incidence of neurological complications and, when reported, of headache and migraine for different transplant types [18–29]. Results are quite variable, but it is difficult

F. Maggioni (✉) · E. Mampreso · M. Ermani · S. Cortelazzo · G. Zanchin
Headache Centre, Department of Neurosciences,
University of Padua, Via Giustiniani, 5, 35128 Padua, Italy
e-mail: ferdinando.maggioni@unipd.it

M. C. Mantovan
Department of Neurology, Hospital of Mestre,
Venice, Italy

P. Rigotti · R. Cadrobbi
Department of General Surgery, University of Padua,
Padua, Italy

F. Mainardi
Headache Centre, Department of Neurology,
Hospital SS. Giovanni e Paolo, Venice, Italy

Table 1 Occurrence of neurological complications in heart, kidney, liver, lung and heart-lung transplants in some studies

Author (reference)	Type of transplant	No. of patients	Neurological complications		Headache		Migraine	
			No. patients	%	No. patients	%	No. patients	%
Hotson et al. 1976 [4]	Heart	83	45	54	nr		nr	
Andrew et al. 1990 [5]	Heart	90	6	7	nr		nr	
Adams et al. 1986 [18]	Kidney	467	140	30	15	3	ns	
Kahan et al. 1989 [19]	Kidney	402	ns		nr		nr	
Christe 1994 [9]	Liver and kidney	576	ns		180	31	nr	
William et al. 1985 [20]	Liver	29	ns		3	10	nr	
de Groen et al. 1987 [21]	Liver	48	13	27	nr		nr	
Stein et al. 1992 [22]	Liver	40	13	33	3	7	nr	
Frank et al. 1993 [23]	Liver	56	ns		18	32	nr	
Moreno et al. 1993 [24]	Liver	143	19	13	nr		ns	
Burkhalter et al. 1994 [7]	Liver	100	34	34	nr		nr	
Steiger et al. 1994 [3]	Liver	34	nr		12	35	6	18
Guarino et al. 1996 [25]	Liver	199	63	32	nr		nr	
Goldstein et al. 1998 [26]	Lung, heart-lung	100	32	32	14	15	nr	
Jarquín-Valdivia et al. 1999 [27]	Heart	137	25	18	nr		nr	
Cemillán et al. 2002 [28]	Heart	205	95	48	21	11	nr	
Kim et al. 2004 [29]	Kidney (cy)	56	nr		ns	2	nr	
Kim et al. 2004 [29]	Kidney (tc)	41	nr		ns	12	nr	

When reported, data regarding headache and migraine are given
nr not reported, *ns* not specified, *cy* cyclosporine, *tc* tacrolimus

to compare them owing to the different methods used. In this study we considered the occurrence of different headache types in a group of renal transplanted patients before and during renal failure (RF), during dialysis, after transplantation.

Methods

A total of 83 consecutive patients (55 males, 28 females; mean age 41.7 ± 11.8 , range 18–63) at least 6 months after transplantation were included in the study. All the patients underwent orthotopic renal transplant at the General Surgery Department of our University. Data on patient age at the time of transplantation and the course of the illness are summarised in Tables 2 and 3. The most frequent diseases underlying RF were glomerulonephritis (53% of patients) and polycystic kidney disease (13%), followed by diabetes mellitus, ureteral malformation and systemic lupus erythematosus. A patient questionnaire was used to collect anamnestic information, with specific regard to pharmacological history and headache characteristics during distinct periods: before RF; during RF; during dialysis treatment; after the transplant. The headaches were classified according to ICHD-II criteria [30]. All the patients underwent a general and neurological

Table 2 Age at transplantation ($n = 83$)

Age	Male	Female
<20	0	1
20–30	8	7
31–40	15	4
41–50	15	11
>50	17	5
Total	55	28

Table 3 Time elapsed in the different conditions ($n = 83$)

Time	Renal failure	Dialysis	Transplantation
1–6 months	2	0	0
6–12 months	17	18	43
1–3 years	18	35	27
3–6 years	20	20	7
>6 years	26	10	6

examination. Blood pressure, weight, blood biochemistry parameters and cyclosporine dosage were measured and records of the same parameters from previous visits were obtained. All the patients were on immunosuppressive therapy with cyclosporine and corticosteroid; in addition,

a large group was being treated with anti-hypertensive therapy.

Considering that all analysed variables were qualitative, a non parametric analysis was performed with the Pearson’s χ^2 and the McNemar’s χ^2 tests. The significant level was set at $P < 0.05$.

Results

The pattern of headache in the 83 patients during the various periods of their history is shown in Table 4. In group A (before RF), 27 patients suffered from headache: 17 migraines without aura (MO), eight episodic tension-type headache (ETTH) and two hypertension-related (HR). In group B (during RF), the 36 patients suffering from headache comprised 20 MO, two ETTH, 13 HR, one metabolic headache (MH). Of those with MO, 12 patients had suffered before RF and eight were new cases. For the other five MO patients in group A, MO ceased in four and one developed HR. The two ETTH cases had also suffered before RF; of the six remaining ETTH patients in group A, three developed HR, whereas in three headache ceased. Out of HR group, 11 were new cases and two patients had already suffered before RF. In group C (during dialysis) (Table 4c), the 33 headache sufferers comprised seven MO, one ETTH, three HR, 22 dialysis headache (DH). All the group C MO patients had been in the same category in group B; of the remaining 13 group B MO patients, MO

ceased in eight and five developed DH. The group C ETTH patient had been in the same category in group B. Of the 22 DH patients 13 were new cases and nine had been categorised in group B (five MO, three HR and one ETTH). In group D (after transplantation), 37 patients suffered of headache: 15 MO, 10 ETTH, two ETTH + MO, two HR, four not classifiable (NC), two cyclosporine related (CY), one OKT3 related headache (OKT3), one primary stabbing headache (PSH). Twenty three of whom were new cases (six MO, seven ETTH, two ETTH + MO, four NC, two CY, one OKT3, one PSH). Conversely, 26 patients suffering from headache (10 MO) before transplant were free of attacks at 6–12 months follow up.

In order to evaluate a possible significance of the different headache occurrence before and after transplant, we subdivided the headache patients into two groups, considering in the first only migraine patients and in the second all the other kind of headaches. In the first group, 17 (20%) patients suffered of MO before the transplant, 15 (18%) MO post transplant, without statistical significance (McNemar’s $\chi^2 P = 0.79$). In the second group, 10 (12%) patients presented headache before transplant, 22 (26.5%) after, with statistical significance (McNemar’s $\chi^2 P = 0.004$).

All patients received immunosuppressive therapy of both cyclosporine and prednisone at dosages depending on the time elapsed since transplantation and clinical condition. To investigate a possible correlation between the headache and levels of cyclosporine and/or creatinine, we examined the post transplant follow-up results at 7 days and 1–3–6–12 months for patients who had cyclosporine and creatinine levels above the normal range. There were no significant differences for both between patients with and without headache (Pearson’s $\chi^2 P = 0.43$ for cyclosporine and $P = 0.73$ for creatinine). We were able to establish a definite relationship with cyclosporine administration only in two cases in which the lowering the high cyclosporine level within the normal range, was followed by headache disappearance.

Furthermore, 64 patients received azotioprine, 73 anti-hypertensive therapy; among the latter, 25 were treated with the beta-blockers, 18 with metoprolol, seven with atenolol. Table 5 summarises the data on the occurrence of MO in transplant patients with and without beta-blocker treatment. Comparison of the data reveals that administration of these anti-hypertensive agents, which are known to protect against migraine, did not influence MO development. Indeed, the onset or disappearance of MO showed no relation with doses nor with the type of beta-blocker used (metoprolol 50–200 mg, atenolol 50–100 mg). Tables 6 and 7 list the patient characteristics and the pattern of migraine attacks for subjects who developed MO after transplantation.

Table 4 Occurrence of headache during the different periods of the history of the patients ($n = 83$)

Type of headache	A		B		C		D	
	N	%	N	%	N	%	N	%
MO	17	20.5	20	24.0	7	8.4	15	18.0
ETTH	8	9.6	2	2.4	1	1.2	10	12.0
MO + ETTH	0	0	0	0	0	0	2	2.4
DH	0	0	0	0	22	26.5	0	0
NC	0	0	0	0	0	0	4	4.8
HR	2	2.4	13	15.7	3	3.6	2	2.4
MH	0	0	1	1.2	0	0	0	0
PSH	0	0	0	0	0	0	1	1.2
CY	0	0	0	0	0	0	2	2.4
OKT3	0	0	0	0			1	1.2
Total	27	32.5	36	43.3	33	39.7	37	44.5

N number of patients, A before renal failure, B during renal failure, C during dialysis, D after transplant, MO migraine without aura, ETTH episodic tension-type headache, DH dialysis headache, NC not classifiable headache, HR hypertension related, MH metabolic headache, PSH primary stabbing headache, CY cyclosporine related headache, OKT3 OKT3 related headache

Table 5 MO patients treated and not treated with beta-blockers in the different conditions

MO	Timing in the assumption of beta blockers		
	Before and after transplant	Introduced after transplant	Never treated
Before and after transplant	1	3	4
After transplant	1	3	4
Disappeared after transplant	0	4	6

Table 6 Patients who developed MO after transplant

Nº	Age	Sex	RF etiology	RF length	Dialysis	Time elapsed after transplant	Symptoms	NE	Therapy
1	48	F	pd	8	2	2	T, A	N	c, fur
2	38	F	nk	13	1	18 m	T, A, MF	N	c, dox, fur, metop, clon
3	20	F	gn	3 m	2	3	T	N	c, fur
4	33	M	gn	1 m	1	7	–	N	all, c, ena, nifed, metop
5	27	F	gn	9	3	1	T	N	at, c
6	47	M	gn	2	1	3	T	N	c, clon, fur, simv
7	30	F	rm	5	3 years 6 months	2	T	N	c
8	22	M	pd	2	6 months	7	–	N	all, c, clonidine, fur, metop

gn glomerulonephritis, r renal failure, m months, rm renal malformation, nk not known, pn pyelonephritis, pd polycystic kidney disease, A asthenia, N normal, T tremor, MF mnesic failure, NE neurologic examination, all allopurinol, at atenolol, c cyclosporine, clon clonidine, dox doxazosin, ena enalapril, fur furosemide, metop metoprolol, nifed nifedipine, simv simvastatin; times in years when non specified

Table 7 Attack features, treatments and associated headache in the patients with MO developed after transplant

Nº	F H	1st attack PT	Frequency of the attacks	Intensity	Treatment	Other headache
1	A	2 days	Every 3 months	Severe	NSADs	–
2	A	3 months	Every 15 days	Moderate-severe	NSADs	ETTH
3	P	5 months	2–3 at months	Severe	NSADs	–
4	A	2 months	Every 5–6 months	Moderate-severe	Rest	ETTH
5	P	1 months	Monthly	Severe	Rest	–
6	P	6–7 months	Monthly	Severe	NSADs	–
7	P	3–4 months	Weekly	Mild-moderate	Rest	–
8	A	1 year	Weekly	Severe	NSADs	–

FH Family history for migraine, A absent, P present, PT post transplant, NSADs not-steroidal anti-inflammatory drugs, ETTH episodic tension-type headache

Finally, the group of patients suffering from MO that persisted after transplantation ($n = 10$) showed no relevant change in the pattern of attacks in either frequency or intensity.

Discussion

The results show that headache is a diffuse problem in the transplant patients, affecting 44.5% of the study subjects and requiring specific treatment or diagnostic procedure in 8%. Comparing with the literature, the percentage of patients with headache is higher, respect to both liver and

kidney transplant patients 31% and to liver transplant patients 7–35% [3, 23]. We found no reports on the prevalence of migraine after isolated kidney transplantation. In the only paper available on kidney transplant, headache affects only 3% of patients but this result is not comparable with ours, since this study considers only the acute complications occurring in the first 3 days after the surgical procedure [2]. Steigler et al. 1994 [3] reported migraine in 18% of liver transplanted patients, in agreement with the results found here.

According with IHS diagnostic criteria of headache induced by substance use or exposure (30), cyclosporine seems not to be a relevant factor in the development of

headache and specifically of migraine; in the only two cases with a definite relationship, the headache was described as continuous, tightening, bilateral in location, and without neurovegetative symptoms, which disappeared on a decrease in cyclosporine dosage. However, we cannot exclude a role of cyclosporine in the genesis of headache not directly related to its high level; since in particular some patients may be predisposed to develop headache. About this point, if we consider that after transplant four patients presented no classifiable headache, condition not present before RF, during RF or during DH periods and situation de novo in four patients, seem possible that this therapy could somehow favour the development of headache, perhaps related to its vasoactive properties [31]; however, the exact mechanisms by which the immunosuppressive drugs could induce or exacerbate headache are unknown. Six of the eight cases who developed MO after transplantation had a low frequency of attacks, which does not seem to be related to the use of a drug taken continuously. In none of these cases, the symptomatology was considered so important as to require modification of cyclosporine use. In two cases, the age on presentation of migraine was relatively advanced (46 and 47 years) and the first attack occurred within 1 month after transplant, casting doubt on a causative mechanism different from simply casualness.

None of the patients reported migraine with aura (MA), a finding that differs from that of Steiger et al. [31], who reported that 5/34 liver transplant patients developed MA after surgery; among different hypothesis, this could possibly be related to the different transplant organ.

During dialysis, the number of patients with headache attributable to this procedure, without correlation with pre-existing headache or migraine, was remarkable. On the other hand, we observed a decrease in the number of MO patients during dialysis. Furthermore, no new MO cases occurred during this period, which was long enough (dialysis duration at least 1 year in 70% of patients and at least 6 months in >98%) to exclude bias due to too short an observation period. We can hypothesise possible mechanisms related to the procedure of dialysis or to biochemical plasma changes in calcitonin gene-related peptide and substance P as recently demonstrated [32].

An important point is the antihypertensive therapy taken by patients, in particular beta-blockers, which represent an important prophylactic treatment. There are no differences for beta-blocker treatment in the distribution of patients who developed MO after transplantation, those with pre-existing MO, or those for whom MO disappeared after transplant. In the three groups of patients with MO, the distribution of the cases with MO developed after transplant, with pre-existing MO or indeed in which disappeared is the same. The new cases with MO in therapy with

beta-blockers are four, in three the introduction of the drug was after transplant in one was pre-existing the transplant. Of the 10 patients in whom MO disappeared, beta-blocker treatment was started after transplantation in four and the remaining six patients were not treated. In conclusion, the treatment with beta-blockers may be a cause that produces some difficulties in the interpretation of the data, but the detailed analysis of the results seems to indicate that the distribution of the patients regarding the appearance or disappearance of MO in the various groups of patients is random.

After kidney transplant, we did not find an increase of MO cases, but a significant increase in the number of non specific headache such as “non classifiable” or ETTH.

Further studies on the occurrence of neurological complications in transplanted patients should take in account also the development of headache specifically of migraine. Besides clarifying the extent of this problem, such investigations could give clues on its causative mechanisms, particularly with regard to immunosuppressive therapy.

Conflict of interest None.

References

1. Patchell RA (1994) Neurological complications of organ transplantation. *Ann Neurol* 36:688–703
2. Adams DH, Ponsford S, Gunson B, Boon A, Honisberger L, Williams A, Buckels J, Elias E (1987) Neurological complications following liver transplantation. *Lancet* 1:949–951
3. Steiger MJ, Farrah T, Rolles K, Harvey P, Burroughs AK (1994) Cyclosporine and headache. *J Neurol Neurosurg Psychiatry* 57:1258–1259
4. Hotson JR, Pedley T (1976) The neurological complications of cardiac transplantation. *Brain* 99:673–694
5. Andrew BT, Hershon JJ, Calanchini P, Avery J, Hill D (1990) Neurologic complication of cardiac transplantation. *West J Med* 153:146–148
6. Sila CA (1989) Spectrum of neurologic events following cardiac transplantation. *Stroke* 20:1586–1589
7. Burkhalter E, Starzl T, Van Thiel DH (1994) Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. *J Hepatol* 21:572–577
8. Kahan BD (1989) Cyclosporine. *N Eng J Med* 321:1725–1738
9. Christie W (1994) Neurological disorders in liver and kidney transplant recipients. *Transplant Proc* 26:3175–3176
10. Wijndick EFM (1999) Neurologic complications in transplant recipients: a bird's-eye view. In: Wijndick EFM (ed) *Neurologic complications in transplant recipients*. Butterworth Heineman, Boston, p 57
11. Matas AJ, Halbert RJ, Barr ML, Helderma JH, Hricik DE, Pirsch JD, Schenkel FA, Siegal BR, Liu H, Ferguson RM (2002) Life satisfaction and adverse effects in renal transplant recipients: a longitudinal analysis. *Clin Transplant* 16:113–121
12. Gharpune VS, Hutchinson RM, Durrant ST (1990) Migraine after bone-marrow transplantation. *Lancet* 335:57
13. Arns W (1994) Kopfschmerzen unter Cyclosporin-Therapie. *DMW* 119:1135

14. Rozen TD, Wijdicks EFM, Hay JE (1996) Treatment refractory cyclosporine-associated headache: relief with conversion to FK-506. *Neurology* 47:1347
15. Maggioni F, Mantovan MC, Moscardo P, Zanchin G (1997) Migraine after heart transplantation: case report and review of the literature. *Nuova Riv Neurol* 7:185–190
16. Maghrabi K, Bohlega S (1998) Cyclosporine-induced migraine with severe vomiting causing loss of renal graft. *Clin Neurol Neurosurg* 100:224–226
17. Toth C, Burak K, Becker W (2005) Recurrence of migraine with aura due to tacrolimus therapy in a liver transplant recipient successfully treated with sirolimus substitution. *Headache* 45:245–254
18. Adams HP, Dawson G, Coffman TJ, Corry RJ (1986) Stroke in renal transplant recipients. *Arch Neurol* 43:113–115
19. Kahan BD, Flechner SM, Lorber MI, Golden D, Conley S, Van Buren CT (1987) Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. *Transplantation* 43:197–204
20. William R, Blackburn A, Neuberger J, Calne Y (1985) Long term use of cyclosporine in liver grafting. *Q J Med* 224:897–905
21. de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom R (1987) Central nervous system toxicity after liver transplantation. *N Engl J Med* 317:861–866
22. Stein DP, Lederman RJ, Vogt DP (1992) Neurological complications following liver transplantation. *Ann Neurol* 31:644–649
23. Frank B, Perdrietz GA, White HM, Marsh JW, Leman W, Woodie ES (1993) Neurotoxicity of FK 506 in liver transplant recipient. *Transplant Proc* 25:1887–1888
24. Moreno E, Gomez SR, Gonzales I, Loinaz C, Garcia I, Perez A, Palomo C, Alvarado A, Maffettone F, Perez-Cerda F, Lumbreras C, Colina F (1993) Neurologic complications in liver transplantation. *Acta Neurol Scand* 87:25–31
25. Guarino M, Stracciari A, Pazzaglia P, Sterzi R, Santilli I, Donato F, D'Alessandro R (1996) Neurological complications of liver transplantation. *J Neurol* 243:137–142
26. Goldstein L, Haug M, Perl J, Perl M, Maurer J, Arroliga A, Mehta A, Kirby T, Higgins B, Stillwell B (1998) Central nervous system complications after lung transplantation. *J Heart Lung Transpl* 17:185–191
27. Jarquin-Valdivia AA, Wijdicks EFM, McGregor C (1999) Neurologic complications following heart transplantation in the modern era: decreased incidence, but postoperative stroke remains prevalent. *Transplant Proc* 31:2161–2162
28. Cemillan CA, Alonso-Pulpon L, Burgos-Lazaro R, Millan-Hernandez I, del Ser T, Liano-Martinez H (2004) Neurological complications in a series of 205 orthotopic heart transplant patients. *Rev Neurol* 38:906–912
29. Kim BS, Lee SG, Hwang S, Park KM, Kim KH, Ahn CS, Moon DB, Ha TY, Song GW, Kim DS, Moon KM, Jung DH (2007) Neurologic complications in adult living donor liver transplant recipients. *Clin Transplant* 21:544–547
30. Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders: 2nd edition. *Cephalalgia* 24(Suppl 1):9–160
31. Yardimci N, Colak T, Sevmis S, Benli S, Zileli T, Haberal M (2008) Neurological complications after renal transplant. *Exp Clin Transplant* 6:224–228
32. Alessandri M, Massanti L, Geppetti P, Bellucci G, Cipriani M, Fanciullacci M (2006) Plasma changes of calcitonin gene related peptide and substance P in patient with dialysis headache. *Cephalalgia* 26:1287–1293